Head to Head Analysis: Aridis Pharmaceuticals (ARDS) and Its Peers
Aridis Pharmaceuticals (NASDAQ: ARDS) is one of 548 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its rivals? We will compare Aridis Pharmaceuticals to similar companies based on the strength of its institutional ownership, profitability, risk, valuation, analyst recommendations, dividends and earnings.
This table compares Aridis Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Aridis Pharmaceuticals Competitors||-1,760.46%||-120.17%||-28.09%|
This is a summary of current ratings for Aridis Pharmaceuticals and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Aridis Pharmaceuticals Competitors||4546||13020||27669||994||2.54|
Aridis Pharmaceuticals currently has a consensus price target of $30.60, suggesting a potential upside of 217.10%. As a group, “Pharmaceutical preparations” companies have a potential upside of 58.38%. Given Aridis Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Aridis Pharmaceuticals is more favorable than its rivals.
Insider & Institutional Ownership
0.2% of Aridis Pharmaceuticals shares are held by institutional investors. Comparatively, 46.3% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 14.9% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Aridis Pharmaceuticals and its rivals gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Aridis Pharmaceuticals||$2.76 million||-$22.10 million||-1.38|
|Aridis Pharmaceuticals Competitors||$2.15 billion||$228.73 million||-3.52|
Aridis Pharmaceuticals’ rivals have higher revenue and earnings than Aridis Pharmaceuticals. Aridis Pharmaceuticals is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Aridis Pharmaceuticals beats its rivals on 6 of the 11 factors compared.
Aridis Pharmaceuticals Company Profile
Aridis Pharmaceuticals, Inc. engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. Its products include AR-301, AR-105, AR-101, AR-401, AR-201, and AR-501. The company was founded by Eric J. Patzer and Vu L. Truong in 2003 and is headquartered in San Jose, CA.
Receive News & Ratings for Aridis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aridis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.